To learn more, please call our Research Department at (513) 936-5388 or (888) 649-4800. Or email abradley@ohcmail.com or jmcguire@ohcmail.com
- CRPC
- Study number:
- GU 64 CC-5013-PC-002 Celgene Corp.
- Protocol title:
- A Phase 3 Study to Evaluate the Efficacy and Safety of Docetaxel and Prednisone with or without Lenalidomide in Subjects with Castrate-Resistant Prostate Cancer
- Status:
- Open